Rock Springs Capital Management’s 10x Genomics TXG Stock Holding History

Rock Springs Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-76,000	Closed	-$10.8M	–	166
2020 Q4	$10.8M	Hold	76,000	–	–	0.23%	110
2020 Q3	$9.48M	Hold	76,000	–	–	0.24%	103
2020 Q2	$6.79M	Hold	76,000	–	–	0.19%	119
2020 Q1	$4.74M	Buy	76,000 +3,500	+5%	+$273K	0.2%	104
2019 Q4	$5.53M	Buy	72,500 +9,000	+14%	+$541K	0.17%	106
2019 Q3	$3.2M	Buy	+63,500	New	+$3.51M	0.13%	121

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Rock Springs Capital Management's TXG Position: Q1 2021 in Review

Rock Springs Capital Management sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 76,000 shares — an estimated $10.8M sold.

Rock Springs Capital Management first reported a position in TXG in Q3 2019 and held it in 6 quarters. The position peaked at $10.8M in Q4 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

Rock Springs Capital Management reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
Rock Springs Capital Management sold 76,000 10x Genomics shares in Q1 2021, an estimated $10.8M.
Rock Springs Capital Management first reported a position in 10x Genomics in Q3 2019 and held it in 6 quarters.
Rock Springs Capital Management's 10x Genomics position peaked at $10.8M in Q4 2020.
324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.